Insight Molecular Diagnostics (IMDX) Prepaid Assets (2016 - 2026)

Insight Molecular Diagnostics has disclosed Prepaid Assets across 11 years of filings, most recently posting $1.0 million for Q1 2026.

• Prepaid Assets for Q1 2026 came in at $1.0 million, down 15.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 15.14% YoY), and the FY2025 annual result was $1.4 million, up 72.96% from the prior year.
• Prepaid Assets came in at $1.0 million for Q1 2026 at Insight Molecular Diagnostics, down from $1.4 million in the prior quarter.
• In the past five years, Prepaid Assets ranged from a high of $2.2 million in Q3 2022 to a low of $595000.0 in Q2 2024.
• The 5-year median for Prepaid Assets is $1.0 million (2026), against an average of $1.1 million.
• Across the five-year window, Prepaid Assets soared 18837.5% in 2022 and plunged 69.09% in 2023, its largest moves.
• Insight Molecular Diagnostics' Prepaid Assets stood at $977000.0 in 2022, then slumped by 34.19% to $643000.0 in 2023, then gained by 27.68% to $821000.0 in 2024, then jumped by 72.96% to $1.4 million in 2025, then decreased by 26.2% to $1.0 million in 2026.
• The last three Prepaid Assets figures came in at $1.0 million (Q1 2026), $1.4 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.